<p>Parameter estimates according to the modeling assumptions: complete, asymptotic or plasma-cell driven kinetics (PCDK) model (95% confidence intervals determined using bootstrap percentile intervals).</p
<p>Parameter estimates for the power-law growth and decay model without autocorrelation.</p
<p>Parameter estimates for the best fit with the CD8+ T cell model (<i>a</i>, <i>r</i>, and <i>k</i>...
<p>The reduced dataset with 35 subjects and 388 plasma concentrations was used. Parameters: CL, clea...
<p>Parameter estimates for the models of target cell kinetics in blood and spleen.</p
<p>Parameter estimates using power-law model (95% confidence intervals determined using bootstrap pe...
<p>Long-term prediction of HAV antibody dynamics obtained with complete and plasma cell driven kinet...
<p>CI<sub>90%</sub> = 90% confidence interval.</p><p>(CI<sub>90%</sub> by bootstrapping).</p
Physiologically-based pharmacokinetic and cellular kinetic models are used extensively to predict co...
<p><b>A</b>: Best fit of the model predictions (lines) to experimentally determined cell fractions a...
<p>Parameter estimates and 95% credible intervals for the categorical variables of the chosen model....
<p>(A) Percentage of models that reach steady-state within 300 minutes as a function of phosphoglyce...
<p>Parameter estimates from the pharmacokinetic-pharmacodynamic time-to-event model.</p
<p>Estimates for baseline rates (unit yr<sup>−1</sup> per cell) of cell-kinetic processes in the two...
<p>Population parameter estimates and relative standard errors (RSE, in %) of the bacterial kinetic ...
Model estimates of relative log(concentrations) and the corresponding ratios of change between the s...
<p>Parameter estimates for the power-law growth and decay model without autocorrelation.</p
<p>Parameter estimates for the best fit with the CD8+ T cell model (<i>a</i>, <i>r</i>, and <i>k</i>...
<p>The reduced dataset with 35 subjects and 388 plasma concentrations was used. Parameters: CL, clea...
<p>Parameter estimates for the models of target cell kinetics in blood and spleen.</p
<p>Parameter estimates using power-law model (95% confidence intervals determined using bootstrap pe...
<p>Long-term prediction of HAV antibody dynamics obtained with complete and plasma cell driven kinet...
<p>CI<sub>90%</sub> = 90% confidence interval.</p><p>(CI<sub>90%</sub> by bootstrapping).</p
Physiologically-based pharmacokinetic and cellular kinetic models are used extensively to predict co...
<p><b>A</b>: Best fit of the model predictions (lines) to experimentally determined cell fractions a...
<p>Parameter estimates and 95% credible intervals for the categorical variables of the chosen model....
<p>(A) Percentage of models that reach steady-state within 300 minutes as a function of phosphoglyce...
<p>Parameter estimates from the pharmacokinetic-pharmacodynamic time-to-event model.</p
<p>Estimates for baseline rates (unit yr<sup>−1</sup> per cell) of cell-kinetic processes in the two...
<p>Population parameter estimates and relative standard errors (RSE, in %) of the bacterial kinetic ...
Model estimates of relative log(concentrations) and the corresponding ratios of change between the s...
<p>Parameter estimates for the power-law growth and decay model without autocorrelation.</p
<p>Parameter estimates for the best fit with the CD8+ T cell model (<i>a</i>, <i>r</i>, and <i>k</i>...
<p>The reduced dataset with 35 subjects and 388 plasma concentrations was used. Parameters: CL, clea...